EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities by Ozlem Yedier-Bayram, Bengul Gokbayrak, Alisan Kayabolen, Ali Cenk Aksu, Ayse Derya Cavga, Ahmet Cingöz, Ezgi Yagmur Kala, Goktug Karabiyik, Rauf Günsay, Beril Esin, Tunc Morova, Fırat Uyulur, Hamzah Syed, Martin Philpott, Adam P. Cribbs, Sonia H. Y. Kung, Nathan A. Lack, Tamer T. Onder, Tugba Bagci-Onder

Get full text

Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival by Ezgi Ozyerli-Goknar, Ezgi Yagmur Kala, Ali Cenk Aksu, Ipek Bulut, Ahmet Cingöz, Sheikh Nizamuddin, Martin Biniossek, Fidan Seker-Polat, Tunc Morova, Can Aztekin, Sonia H. Y. Kung, Hamzah Syed, Nurcan Tuncbag, Mehmet Gönen, Martin Philpott, Adam P. Cribbs, Ceyda Acilan, Nathan A. Lack, Tamer T. Onder, H. T. Marc Timmers, Tugba Bagci-Onder

Get full text